The CAPTAIN trial shows faster recovery, fewer complications, and better early function with the minimally invasive therapy in men with intermediate-risk prostate cancer.

As a result, researchers have explored less invasive options that aim to treat the cancer while preserving quality of life. One such approach is TULSA, which uses real-time MRI guidance to deliver ...

The 2026 European Association of Urology (EAU) annual meeting featured a late-breaking abstracts session and a presentation by Dr. Laurence Klotz discussing initial perioperative outcomes of CAPTAIN, ...

Esaote presents its new and innovative technology dedicated to urology: the exclusive Prostate Attention Map (PAM), now ...

Discusses First Clinical Outcomes and Precision of TULSA from the CAPTAIN Trial in Prostate Cancer March 13, 2026 11:30 ...

The technology is available on the new MyLabE85 GTS Edition that will be showcased together with the brand new MyLabC30 GTS ...

Men could soon be offered quick MRI scans lasting under 15 minutes to detect prostate cancer earlier, under new recommendations from international experts.

At ECR 2026, UII reaffirmed its AI development principles, which are anchored in clinical validation, regulatory rigor, and measurable outcomes. This approach transforms radiology knowledge into a ...

PROCEPT BioRobotics (Nasdaq: PRCT), today announced the international expansion of the HYDROS Robotic System, the company’s next-generation platform for delivering Aquablation therapy to treat benign ...

Nearly 300 abstracts on prostate cancer research from around the world will be presented at the European Association of Urology Congress (EAU26 ...